Liver Transplantation
Conditions
Keywords
delirium, incidence, dexmedetomidine
Brief summary
To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative delirium in liver transplant patients in the ICU. Single center prospective randomized placebo controlled clinical trial 0.1mcg/kg/hr of dexmedetomidine or equivalent amount of saline infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery. Outcomes will be assessed up to 1 week or transfer to ward, whichever comes first.
Interventions
DRUGPrecedex
infusion of 0.1mcg/kg/hr of precedex
DRUGplacebo control
placebo
Sponsors
Hospira, now a wholly owned subsidiary of Pfizer
Seoul National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients (18years old or older) undergoing living-donor or deceased-donor liver transplantation
Exclusion criteria
* Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive at baseline, who have neurologic deficits at baseline, or who are allergic to dexmedetomidine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| analysis of the incidence of postoperative delirium in liver transplant patients in the ICU. | 1 week or transfer to ward, whichever comes first. | after August 25, 2014 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| analysis of the duration of postoperative delirium, ICU length of stay in liver transplant patients in the ICU. | 1 week or transfer to ward, whichever comes first. | after August 26, 2014 |
Countries
South Korea
Outcome results
None listed